Get started
Author

Mimoza Bodén

Observed name: Mimoza Boden
Institution: BioInvent (Sweden)
Observed institution: BioInvent (Sweden)
ORCID: 0009-0002-1806-5710
Observed ORCID: 0009-0002-1806-5710
OpenAlex ID: A5030889033
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors
2022 · Monika Semmrich, Jean-Baptiste Marchand, et al. · Journal for ImmunoTherapy of Cancer · 36
PDF
Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al. · Cancer Research · 3
1368 Preclinical development of an agonistic anti-TNFR2 antibody (BI-1910) for cancer immunotherapy
2023 · Linda Martensson, Petra Holmkvist, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al. · Cancer Immunology Research · 1
PDF
Supplementary Fig 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 5 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 4 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Table 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Data from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 3 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 10 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 8 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 9 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 7 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 2 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Fig 6 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Supplementary Materials and Methods from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
2026 · Linda Mårtensson, Petra Holmkvist, et al.
Data from A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al.
Supplementary Figure S3 from A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al.
PDF
Supplementary Figure S1 from A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al.
PDF
Supplementary Figure S2 from A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al.
PDF
Supplementary Table 5 from A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al.
PDF
Supplementary Table 3 from A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al.
PDF
Supplementary Table 1 from A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al.
PDF
Supplementary Table 2 from A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy
2025 · Kirstie L.S. Cleary, Monika Semmrich, et al.
PDF
Works count: 26
Citation count: 43
H-index: 3
I10-index: 1
Year
Topic
Type